Author: Ravi Shankar

        
– Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib

– New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships

TARPON SPRINGS, Fla., September 28, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—
today announced that it has expanded the capabilities of its in-house medical laboratory to include proteomics and cell line research.

The new capabilities build on the laboratory’s existing transcriptomics research and CLIA clinical testing services and are expected to support Allarity in several areas. Internally, the expanded capabilities will allow the Company to conduct additional research into the mechanism of action of its lead asset, stenoparib. Externally, these capabilities broaden the range of research projects and laboratory services that Allarity can offer to existing and prospective customers.

Proteomics has become an increasingly important component of translational cancer research by providing information about protein expression, signaling pathways and the molecular mechanisms involved in tumor growth, progression and treatment response. Integrating proteomic analysis with transcriptomic and cell-based research can provide a more comprehensive view of tumor biology and help identify therapeutic targets and modulators of drug response.

“By combining transcriptomics, proteomics and cell line research within our own laboratory infrastructure, we can generate a broader set of molecular insights to support our stenoparib development program. We expect this to be particularly valuable as we continue to deepen our dialogue with leading oncologists and other stakeholders, both to better understand stenoparib’s differentiated mechanism of action and to further sharpen our understanding of the cancer indications in which it may have the greatest potential,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “At the same time, these expanded capabilities allow us to broaden the scientific services we can provide to external partners.”

Allarity’s medical laboratory is equipped with an nCounter® Pro instrument that supports the Company’s transcriptomics research and CLIA clinical services. The platform can now also be applied to proteomics research using the nCounter® Human Tumor Signaling Protein Panel, which measures approximately 300 protein targets. Together with the addition of cell line research capabilities, this significantly expands the range of molecular and preclinical research that Allarity can conduct in-house.

The expanded laboratory capabilities will not affect the Company’s current cash runway. Rather, these may generate significant cost efficiencies by enabling more research activities to be conducted in-house.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.

Allarity has completed its first Phase 2 trial evaluating stenoparib in patients with advanced ovarian cancer. The trial demonstrated promising and durable clinical benefit in patients with ovarian cancer who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from the trial were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature.

Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol focused on patients with platinum-resistant ovarian cancer, which began enrolling patients in the summer of 2025. The amended protocol enrolls only platinum-resistant or platinum-ineligible patients and is designed to advance the clinical development of stenoparib toward potential FDA approval.

In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment, and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

The DRP methodology is based on the comparisons of sensitive and resistant human cancer cell lines, and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.

The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the anticipated benefits of the Company’s expanded laboratory capabilities, including the use of proteomics and cell line research to support mechanism-of-action studies for stenoparib; the potential for these capabilities to generate additional molecular insights; and the Company’s ability to broaden the research and laboratory services offered to existing and prospective external partners. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully implement and utilize its expanded proteomics and cell line research capabilities; the possibility that these capabilities may not generate the anticipated scientific insights or support the development of stenoparib as expected; operational, technical, regulatory or quality-related challenges associated with laboratory service delivery; the Company’s ability to attract and retain external customers for its expanded laboratory services; and the Company’s overall financial resources. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

###

Company Contact:
     investorrelations@allarity.com
        
Media Contact:
     Thomas Pedersen
     Carrotize PR & Communications
     +45 6062 9390
     tsp@carrotize.com

Attachment

• Allarity Therapeutics Expands Laboratory Capabilities

ASML reports transactions under its current share buyback program

VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML’s current share buyback program.

Date	Total repurchased shares	Weighted average price	Total repurchased value
21-Sep-26	25,500	€1,479.91	€37,737,595
22-Sep-26	29,000	€1,492.35	€43,278,199
23-Sep-26	43,000	€1,510.06	€64,932,593
24-Sep-26	57,700	€1,505.71	€86,879,282
25-Sep-26	10,000	€1,533.55	€15,335,519

ASML’s current share buyback program was announced on 28 January 2026. Further details are available on our website.

This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).

About ASML

ASML is a leading supplier to the semiconductor industry. The company provides chipmakers with hardware, software and services to mass produce the patterns of integrated circuits (microchips). Together with its partners, ASML drives the advancement of more affordable, more powerful, more energy-efficient microchips. ASML enables groundbreaking technology to solve some of humanity’s toughest challenges, such as in healthcare, energy use and conservation, mobility and agriculture. ASML is a multinational company headquartered in Veldhoven, the Netherlands, with offices across EMEA, the US and Asia. Every day, ASML’s more than 44,100 employees (FTE) challenge the status quo and push technology to new limits. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. Discover ASML – our products, technology and career opportunities – at www.asml.com.

Media Relations contacts Monique Mols, phone +31 6 528 444 18

Investor Relations contacts Jim Kavanagh, phone +31 40 268 3938 Pete Convertito, phone +1 203 919 1714 Peter Cheang, phone +886 3 659 6771

        

Recognition honors Kaltura’s Agentic Avatars for turning static content into real-time, guided conversations, resulting in substantial improvements in audience

New York, New York, Sept. 28, 2026 (GLOBE NEWSWIRE) — Kaltura (Nasdaq: KLTR), the Agentic Digital Experience company, today announced that it has won Best Interactive Content Platform in the 2026 Digiday Technology Awards for the Kaltura Agentic Avatars. The Digiday Technology Awards recognize companies embracing AI and automation tools to enhance personalized experiences, enable precise targeting and drive performance across platforms and channels. 

Kaltura’s Agentic Avatars turns an organization’s own video and knowledge into live, conversational, agentic experiences that do more than answer a question. It builds the experience around the answer, assembling video clips, text, charts, and event details into a layout shaped by the conversation and by what it already knows about the person, grounded in verified, on-brand knowledge and available across languages, around the clock. 

The results are measurable. Across Kaltura deployments, Agentic Avatars have driven substantial increases in both audience engagement and the number of sales-qualified leads, while lowering live support costs by handling first-line guidance and escalating only the conversations that need a human. 

“The way people engage with information is changing faster than it has in decades. Static pages and endless search are giving way to intelligent, conversational experiences that understand what someone needs and respond in the moment,” said Ron Yekutiel, Co-Founder, Chairman, President and Chief Executive Officer of Kaltura. “Agentic Avatars are how enterprises make that shift, turning their knowledge into experiences that see, listen, guide, and act on behalf of the people they serve. We believe the future of digital experience is agentic, and being named Best Interactive Content Platform by Digiday tells us the market agrees .” 

The recognition follows a year of continued expansion of Kaltura’s AI portfolio, including its Avatar Video Production Studio, Avatar-Powered Roleplay for enterprise learning and training, and advances in real-time emotional intelligence for Agentic Avatars. Kaltura and PathFactory, a Kaltura company, have also received recent recognition from Gartner, Forrester, IDC, ISG Research, Frost & Sullivan and Aragon Research across conversational AI, enterprise video, virtual events and related digital experience markets. 

About Kaltura 

Kaltura’s mission is to power rich, agentic digital experiences across organizational journeys for customers, employees, learners, and audiences. Its platform combines intelligent content creation, enterprise-grade content management and intelligence, and multimodal conversational engagement capabilities. Kaltura serves leading enterprises, financial institutions, educational institutions, media and telecom providers, and other organizations worldwide. For more information, visit www.kaltura.com.  

CONTACT: Nohar Zmora 

SVP, Head of Marketing 

pr.team@kaltura.com 

 

The recognition highlights Paychex’s financial strength, innovation, and sustainability

• Paychex earned 5-out-of-5-stars on Newsweek’s America’s Greatest Companies 2026 list
• The recognition evaluates companies across four pillars: financial strength, market performance as an American employer, innovation, and environmental sustainability

ROCHESTER, N.Y., Sept. 28, 2026 (GLOBE NEWSWIRE) — Paychex (Nasdaq: PAYX), a leading provider of expert-enabled HR, payroll, and benefits, today announced it has been named to Newsweek’s America’s Greatest Companies 2026, earning a 5-out-of-5-star rating on the national list.

Recognized Across Every Pillar of Performance
The recognition reflects the strength of Paychex’s business across every dimension that Newsweek and Plant-A Insights Group measure. The America’s Greatest Companies ranking evaluates U.S.-based, publicly traded companies on four pillars: financial strength, market performance as an American employer, innovation, and environmental sustainability.

“This recognition reflects the strength of Paychex and our commitment to delivering long-term value for all our stakeholders,” said John Gibson, Paychex president and CEO. “Our financial performance, dedicated employees, responsible business practices, and culture of innovation all contribute to our success. AI is accelerating what is possible, and we are investing in it thoughtfully to enhance our solutions, empower our teams, and ultimately deliver on our purpose of helping businesses succeed.”

Demonstrated Commitment to AI and Innovation
The national recognition comes as Paychex scales WISE (Workforce Intelligence Strengthened by Expertise), its AI-powered intelligence engine embedded across its HCM platforms – Paychex Flex®, Paycor®, and SurePayroll. Early results from more than 50,000 businesses using WISE show it is helping customers catch approximately 90% of payroll errors before they happen and resolve service requests faster.

A Proven Track Record of Recognition
Earlier this year, Paychex was named to Human Resource Executive’s Top HR Products of the Year, Newsweek’s Most Trustworthy Companies in America, and Ethisphere’s World’s Most Ethical Companies list for the 18th time.

To learn more about Paychex’s awards and honors, visit the awards page.

About Paychex
Paychex, Inc. (Nasdaq: PAYX) provides a comprehensive suite of expert-enabled technology and advisory solutions that help businesses manage HR, payroll, and benefits. Serving approximately 840,000 customers and paying 1 in 11 U.S. private sector workers, Paychex combines scale, trusted expertise, and innovation to help businesses succeed. Built on more than 50 years of workforce experience and one of the industry’s largest proprietary HR datasets, Paychex’s WISE agentic AI engine embeds intelligence directly into workflows to improve productivity, enhance decision-making, and deliver better outcomes. Learn more at paychex.com.

Media Contact
Tracy Volkmann
Paychex, Inc.
Manager, Public Relations
(585) 387-6705
tvolkmann@paychex.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c0b0009-8f4b-4585-91b3-e7ac800bb28c

Study advances development of Lantheus’ investigational GRPR-targeted PET imaging program for prostate cancer

BEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the first patient has been dosed in SPARROW NCT07831824, a Phase 2/3 registrational trial evaluating LNTH-2401 (⁶⁸Ga-DOTA-RM2). LNTH-2401 is an investigational gallium-68-labeled positron emission tomography (PET) imaging agent that targets the gastrin-releasing peptide receptor (GRPR), a biomarker that is highly expressed in many prostate cancers.

SPARROW is an open-label, non-randomized, multicenter Phase 2/3 study that includes an initial Phase 2 dose optimization period followed by a Phase 3 diagnostic performance period. The Phase 3 co-primary endpoints are sensitivity and specificity of LNTH-2401 PET/CT imaging compared with histopathology. The Phase 3 portion of the trial is expected to enroll approximately 400 participants and will evaluate diagnostic performance, safety and tolerability.

“Accurate characterization of disease remains critically important in prostate cancer, particularly as treatment decisions become increasingly personalized,” said Harshad R. Kulkarni, MD, Chief Medical Advisor at BAMF Health and a principal investigator in the SPARROW study. “We are pleased to have dosed the first patient at BAMF Health, where our integrated molecular imaging, radiopharmacy and clinical trials infrastructure supports the evaluation of emerging radiopharmaceutical technologies. GRPR represents a promising and biologically distinct target in prostate cancer, and SPARROW will help define the role GRPR-targeted PET may play in disease detection and characterization.”

GRPR is highly expressed in many primary prostate cancers and has a biologic expression pattern distinct from PSMA. Emerging research suggests GRPR-targeted imaging may provide additional insight in certain tumors that are not optimally characterized using PSMA-directed approaches alone.¹

“Dosing the first patient in SPARROW represents a significant step forward for our pipeline and underscores our commitment to advancing innovative radiopharmaceuticals across the prostate cancer care continuum,” said Ludger Dinkelborg, Head of Research and Development at Lantheus. “As the leader in prostate cancer PSMA PET imaging, LNTH-2401 has the potential to expand our understanding of prostate cancer biology through a complementary imaging target. This program reflects our broader strategy to build a focused pipeline of differentiated radiodiagnostics that may support more informed clinical decision-making.”

About SPARROW
SPARROW is an open-label, non-randomized, multicenter Phase 2/3 clinical trial evaluating investigational 68Ga-LNTH-2401 PET/CT imaging in prostate cancer. The study consists of a Phase 2 dose optimization period followed by a Phase 3 diagnostic performance period.

During Phase 2, up to 12 imaging-evaluable participants with newly diagnosed or biochemically recurrent prostate cancer will receive 68Ga-LNTH-2401 PET/CT imaging to determine the optimal administered activity and imaging time window. Phase 2 will also assess biodistribution, radiation dosimetry, image quality, safety and tolerability. Data from participants with GRPR-positive lesions are expected to support selection of the administered activity and imaging time window for Phase 3.

During Phase 3, approximately 400 participants with newly diagnosed prostate cancer who are at least high risk or have suspected metastatic disease and are eligible for radical prostatectomy with pelvic lymph node dissection will undergo 68Ga-LNTH-2401 PET/CT imaging using the optimized imaging parameters selected during Phase 2.

The Phase 3 co-primary endpoints are participant-level sensitivity and specificity of 68Ga-LNTH-2401 PET/CT imaging compared with histopathology. Secondary diagnostic performance assessments include positive predictive value (PPV), negative predictive value (NPV), regional detection performance, comparative summaries versus conventional imaging and/or PSMA PET imaging where applicable, and assessment of inter-reader and intra-reader agreement. Safety and tolerability will also be evaluated.

About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for more than 70 years. For more information, visit www.lantheus.com.

Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “can,” “continue,” “could,” “future,” “potential,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include (i) the timing and potential outcomes of clinical studies, including SPARROW, evaluating the use of LNTH-2401 for the detection and characterization of prostate cancer; (ii) our ability to develop LNTH-2401 as a PET imaging agent; and (iii) the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com

¹Gastrin-Releasing Peptide Receptor (GRPR) as a Novel Biomarker and Therapeutic Target in Prostate Cancer. National Library of Medicine. Published March 5, 2024. Accessed September 10, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC10916925/

FRISCO, TX, Sept. 28, 2026 (GLOBE NEWSWIRE) — Comstock Resources, Inc. (NYSE and NYSE Texas: CRK) (“Comstock” or the “Company”) announced today that in conjunction with the Azerbaijan International Investment Forum, Comstock and SOCAR entered into a Framework Agreement memorializing the previously announced strategic partnership and SOCAR’s $1.65 billion investment in the Haynesville Shale, North America’s premier natural gas basin with close proximity to the Gulf of America’s LNG export facilities. The Framework Agreement memorializes both parties’ mutual commitment to negotiate and execute a definitive purchase and sale agreement consistent with the previously announced letter of intent related to the $1.65 billion strategic partnership. The definitive purchase and sale agreement is anticipated to be signed no later than October 31, 2026, and the transaction is expected to be closed by the end of 2026.  

To maximize the value of the Haynesville shale assets, Comstock and SOCAR will work together to explore opportunities for SOCAR to market natural gas produced from the Haynesville Shale assets attributable to Comstock’s interest for sale as LNG in international markets outside the United States. The parties will be focused on identifying potential offtake counterparties, evaluating pricing structures and assessing logistical and regulatory considerations associated with such international marketing arrangements.

The strategic partnership is part of a broader relationship between the United States and Azerbaijan under the protocol of the 1^st Azerbaijan-United States Economic Dialogue that was signed in June 2026. The Azerbaijan-United States Framework for Securing of Supply in the Mining and Processing of Critical Minerals and Rare Earths was signed by the Azerbaijan Minister of Economy and the U.S. Assistant Secretary of State for Economic, Energy and Business Affairs. The agreement highlights that the United States and Azerbaijan have a long history of cooperation in the oil and gas sector and share a commitment to affordable, abundant energy.

About Comstock Resources

Comstock Resources, Inc. is a leading independent natural gas producer with operations focused on the development of the Haynesville shale in North Louisiana and East Texas. The Company’s stock is traded on the NYSE and the NYSE Texas under the symbol CRK.

About SOCAR

SOCAR is a global integrated energy company headquartered in Azerbaijan. The company operates across the energy value chain, from oil and gas exploration and production to refining, petrochemicals, transportation, trading, and distribution. With a broad international footprint, SOCAR contributes to the energy security of Azerbaijan and its strategic partners while advancing sustainable development.

Forward-Looking Statements

This press release may contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the expected execution of a definitive agreement, the expected timing and completion of the proposed transaction, the receipt of required regulatory approvals, the anticipated use of proceeds, expected leverage and interest savings and future development plans. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described herein, including the risk that a definitive agreement is not executed, that required approvals are not obtained or are delayed, or that the transaction is not completed on the terms described or at all. Although the Company believes the expectations in such statements to be reasonable, there can be no assurance that such expectations will prove to be correct. Information concerning the assumptions, uncertainties and risks that may affect the actual results can be found in the Company’s filings with the Securities and Exchange Commission (“SEC”) available on the Company’s website or the SEC’s website at sec.gov.

Ron Mills
Vice President of Finance and Investor Relations
Comstock Resources
972-668-8834
rmills@comstockresources.com

CONTACT: Ron Mills
VP - Finance and Investor Relations
Comstock Resources
972-668-8834
rmills@comstockresources.com

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.

“We are delighted to welcome two distinguished commercialization and life science leaders to the Humacyte Board as we continue to expand our ongoing Symvess^® launch and prepare for our planned commercial launch of the ATEV in the dialysis access indication,” said Dr. Laura Niklason, Founder, President, and Chief Executive Officer of Humacyte. “Scott Coward brings a track record of success through his leadership at Exact Sciences and has significant experience in board service and executive leadership within publicly traded life sciences companies. Paul Kuznik has extensive experience in vascular healthcare and cardiovascular devices, including extensive leadership roles in commercialization, enterprise leadership, manufacturing, strategic planning, and physician engagement. We look forward to their contributions as we work toward our anticipated U.S. market launch in dialysis.”

Scott Coward served as Executive Vice President, Chief Legal Officer, Chief Administrative Officer and Secretary of Exact Sciences Corporation from January 2015 to December 2022. Mr. Coward led the integration of Genomic Health Corp. following its acquisition by Exact Sciences. He also served on the Exact Sciences board of directors from December 2022 to March 2026. Mr. Coward has been an attorney at K&L Gates since July 2026 and was previously a partner in the firm from 2008 through 2014. During that tenure, he served in different leadership roles, including as the managing partner of the Raleigh office. Mr. Coward brings significant experience in public company board service and corporate governance, executive leadership within publicly traded life sciences companies, mergers and acquisitions and post-acquisition integration, executive compensation, compliance and legal affairs, organizational leadership during periods of substantial growth and change, and has partnered with executive management teams and boards through transformational corporate events. Mr. Coward received his J.D. from Columbia Law School and his B.S. from the University of North Carolina at Chapel Hill. He has been appointed to the Company’s Audit Committee.

“I am honored to join the Humacyte Board of Directors at such an exciting time for the Company,” said Mr. Coward. “Humacyte’s pioneering work in regenerative medicine has the potential to transform patient care, and I look forward to working with the Board and management team to support the Company’s continued growth and long-term success.”

Paul Kuznik is a medical technology executive whose career spans more than three decades in vascular healthcare, cardiovascular devices, and medical diagnostics. Mr. Kuznik served as the Chief Executive Officer and a member of the Board of Directors from 2015 to 2018 at Bolton Medical, a developer of endovascular technologies for complex aortic disease, which was acquired by Terumo Corporation. Following the acquisition, Mr. Kuznik remained with Terumo Corporation, one of Japan’s leading global medical technology companies. He helped lead the integration of Bolton Medical with Vascutek to create Terumo Aortic and subsequently served as President of Terumo Aortic United States from 2019 to 2020 and as President of Terumo Aortic North America from 2020 to 2023. Mr. Kuznik brings extensive experience in commercialization, enterprise leadership, organizational integration, strategic planning, manufacturing, clinical affairs, regulatory oversight, quality systems, physician engagement and board governance. Mr. Kuznik is a graduate of the United States Military Academy at West Point and served as an officer in the United States Army. He has been appointed to the Company’s Commercial Committee.

“I’m thrilled to join the Board of Directors at Humacyte as the Company’s regenerative medicine technologies have the potential to make a significant impact across numerous markets while benefiting patients throughout the world,” said Mr. Kuznik. “I’m excited to work with the Board of Directors and Humacyte in our efforts to expand both physician and patient access to the innovative regenerative vascular solutions offered by the Company.”

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/debe51f6-5e18-4813-9829-d8e85bd71f10
https://www.globenewswire.com/NewsRoom/AttachmentNg/4e6163ac-4843-48ad-b0bb-76203e9bda00

Initial data expected in the first half of 2027

LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (“DMD”).

“Dosing the first patient in our Phase 2 clinical trial of rinvatercept represents an important step in advancing our neuromuscular development strategy, and reflects the progress of our team as we continue to advance Keros’ clinical pipeline,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “Rinvatercept is designed to modulate key regulators of muscle and bone biology, and we look forward to generating clinical data to inform its potential to treat patients with DMD.”

“DMD, despite advances in treatment, continues to place a significant burden on patients and their families, and the need for additional options remains high,” said Gina O’Grady, B.H.B., MBChB, Ph.D., pediatric neurologist at Starship Children’s Hospital. “Rinvatercept’s mechanism established in preclinical studies provides a compelling rationale for clinical evaluation in DMD. This trial represents an important opportunity to assess its potential impact across both ambulatory and non-ambulatory patients with DMD.”

About the Rinvatercept Phase 2 Clinical Trial (NCT07704099)

The rinvatercept Phase 2 clinical trial is an open-label, multi-cohort basket clinical trial in patients with DMD. The primary objective of this trial is to assess the safety and tolerability of rinvatercept in late-ambulatory and early non-ambulatory patients with DMD. The key secondary objectives of this trial are to evaluate pharmacokinetics, anti-drug antibodies, body composition and comprehensive functional improvements (skeletal muscle, motor, cardiac and pulmonary).

About Rinvatercept

Rinvatercept is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB that is fused to the portion of the human antibody known as the Fc domain. Rinvatercept is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A, which are negative regulators of muscle and bone mass and strength, to improve skeletal muscle regeneration, increase muscle size and strength, inhibit and reduce fibrosis, inhibit inflammation, reduce fat accumulation and improve bone health through bone anabolic mechanisms. We are developing rinvatercept for the treatment of DMD and for the treatment of amyotrophic lateral sclerosis (“ALS”).

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of DMD and for the treatment of ALS. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “forward,” “potential,” “expect” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: the expected timing of initial data from the Phase 2 clinical trial of rinvatercept in patients with DMD; the potential benefits of rinvatercept, including its potential impact in ambulatory and non-ambulatory patients with DMD; and the progress and objectives of the Phase 2 clinical trial of rinvatercept in DMD. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 3, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Justin Frantz
jfrantz@kerostx.com
617-221-6042

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a Safe Harbor Financial (“Safe Harbor” or the “Company”) (NASDAQ: SHFS), a leading fintech platform serving the banking, lending, and financial services needs of the regulated cannabis and hemp industries, today announced that its Board of Directors has approved a reverse stock split of the Company’s common stock, par value $0.0001 per share, at a ratio of 1-for-12 (the “Reverse Stock Split”).

The Reverse Stock Split was approved by stockholders at a special meeting of the Company’s stockholders held on November 6, 2025, and is expected to become effective at 12:01 a.m. Eastern Time on September 30, 2026. The Company’s common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Stock Market LLC on September 30, 2026 under the existing ticker symbol “SHFS” with a new CUSIP number of 824430 409.

At the effective time of the Reverse Stock Split, every twelve issued and outstanding shares of the Company’s common stock will be automatically combined into one share of common stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares will receive a number of shares of common stock as rounded up to the nearest whole share.

About Safe Harbor:

Safe Harbor is a cannabis-exclusive financial platform delivering smarter banking, lending, payments and business services tailored to how the cannabis industry actually operates. As one of the original pioneers of compliant financial operations support and cannabis banking consulting in the U.S., Safe Harbor has assisted in the processing of more than $35 billion in cannabis-related depository funds across 41 states and territories. Through its proprietary Cannabis Banking Solutions™ Platform and network of regulated financial institution partners, Safe Harbor empowers cannabis operators to gain clarity, control and confidence in their financial operations. From daily banking to long-term growth, Safe Harbor provides real solutions and personal support — built exclusively for cannabis. Safe Harbor is a financial technology company, not a bank. Banking services are provided by our partner financial institutions. For more information, visit shfinancial.org.

Cautionary Statement Regarding Forward-Looking Statements:

Certain information contained in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included herein may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements may include, but are not limited to, statements with respect to the timing, completion and benefits of the Reverse Stock Split. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “outlook,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Safe Harbor’s filings with the U.S. Securities and Exchange Commission. Safe Harbor undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Safe Harbor Investor Relations Contact:

ir@SHFinancial.org

Safe Harbor Media Relations Contact:

safeharbor@kcsa.com

COLUMBUS, Ohio, Sept. 28, 2026 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), today announced the promotion of Michael J. Gayford to Chief Operating Officer (“COO”), effective immediately.

In his expanded role, Mr. Gayford will assume operational responsibility for the Company’s North American operations, and Arnold Alanis, Executive Vice President of Operations in Mexico, will report to him. Gayford will also continue to focus on driving operational excellence, overseeing program management, advancing research and development initiatives, and executing strategic programs designed to accelerate growth and improve operational performance.

Mr. Gayford joined Core Molding Technologies in 2023 and has more than 25 years of manufacturing, engineering, and operational leadership experience. Throughout his tenure at Core, he has played a key role in strengthening operational execution, advancing technology initiatives, and supporting the Company’s strategic transformation.

“I am pleased to announce Mike Gayford’s promotion to Chief Operating Officer,” said Eric Palomaki, President and Chief Executive Officer. “Mike has been instrumental in advancing our operational capabilities and driving meaningful improvements across the organization. His leadership, strategic vision, and commitment to excellence have contributed significantly to our success, and we are confident he will continue to make a positive impact in this expanded role.”

“My three years at Core have been exciting, and I am honored to take on this new role,” said Mike Gayford. “I am privileged to work with such a talented team and look forward to advancing operational excellence, delivering value to our customers, and supporting Core’s long-term growth. Together, we are well positioned to build on our momentum and pursue new opportunities.”

Michael J. Gayford joined the company in March 2023 as Vice President of Operations. Mr. Gayford was promoted to Executive Vice President of Operations in 2025, where he oversaw multi-site manufacturing operations across the United States and Canada, and led the company’s Advanced Manufacturing Engineering and Research and Development Organizations. Mr. Gayford has more than 25 years of experience in engineering, manufacturing, and operational leadership, including more than 17 years in composite manufacturing. Mr. Gayford earned his Bachelor of Science in Mechanical Engineering Technology from Alfred State College.

About Core Molding Technologies, Inc.

Core Molding Technologies is a leading engineered materials company specializing in molded structural products, principally in medium- and heavy-duty truck, powersports, building products, and industrial and utility industries across the United States, Canada, and Mexico. The Company operates in one operating segment as a molder of thermoplastic and thermoset structural products. The Company’s operating segment consists of one reporting unit, Core Molding Technologies. The Company offers customers a wide range of manufacturing processes to fit various program volume and investment requirements. These thermoset processes include compression molding of sheet molding compound (“SMC”), resin transfer molding (“RTM”), liquid molding of dicyclopentadiene (“DCPD”), spray-up and hand-lay-up. The thermoplastic processes include direct long-fiber thermoplastics (“DLFT”) and structural foam and structural web injection molding. Core Molding Technologies serves a wide variety of markets, including the medium and heavy-duty truck, marine, automotive, agriculture, construction, and other commercial products. The demand for Core Molding Technologies’ products is affected by economic conditions in the United States, Mexico, and Canada. Core Molding Technologies’ operations may change proportionately more than revenues from operations.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws that are subject to risks and uncertainties. These statements often include words such as “believe”, “anticipate”, “plan”, “expect”, “intend”, “will”, “should”, “could”, “would”, “project”, “continue”, “likely”, and similar expressions. In particular, this press release may contain forward-looking statements about the Company’s expectations for future periods with respect to its plans to improve financial results, the future of the Company’s end markets. Factors that could cause actual results to differ from those reflected in forward-looking statements relating to our operations and business include: dependence on certain major customers, and potential loss of any major customer due to completion of existing production programs or otherwise; business conditions in the plastics, transportation, power sports, utilities and commercial product industries (including changes in demand for production); the availability and price increases of raw material,; general macroeconomic, social, regulatory and political conditions, including uncertainties surrounding volatility in financial markets; the imposition of new or increased tariffs and the resulting consequences; safety and security conditions in Mexico; costs and other resources related to Core Molding Technologies’ efforts to expand its customer base and grow its business, and provide on-time delivery to customers; ; the Company’s decision to pursue new products and initiatives to quote and execute manufacturing processes for new business, acquire raw materials, address inflationary pressures, regulatory matters and labor relations; the ability to successfully identify, evaluate and manage potential acquisitions and to benefit from and properly integrate any completed acquisitions; the Company’s financial position or other financial information; inadequate insurance coverage to protect against potential hazards; equipment and machinery failure; product liability and warranty claims; cybersecurity incidents or other similar disruptions; and other risks and uncertainties described in the Company’s filings with the SEC. These statements are based on certain assumptions that the Company has made in light of its experience as well as its perspective on historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from the anticipated results because of certain risks and uncertainties, including those included in the Company’s filings with the SEC. There can be no assurance that statements made in this press release relating to future events will be achieved. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by such cautionary statements.

Company Contact:
Core Molding Technologies, Inc.
Alex Panda
Executive Vice President & Chief Financial Officer
apanda@coremt.com

Investor Relations Contact:
Three Part Advisors, LLC
Sandy Martin or Steven Hooser
214-616-2207